Bristol-Myers Squibb Reports 3% Revenue Growth to $11.489 Billion in Q1 2026

Bristol-Myers Squibb Company (BMS) reported its financial results for the first quarter of 2026, revealing total revenues of $11.489 billion, a 3% increase from $11.201 billion in the same period last year. The growth was primarily driven by a 3% rise in net product sales, which reached $11.168 billion, up from $10.886 billion in the prior year. The company’s net earnings attributable to BMS were $2.677 billion, or $1.31 per diluted share, compared to $2.456 billion, or $1.20 per diluted share, in the first quarter of 2025. The increase in earnings was attributed to lower amortization of acquired intangible assets, despite higher impairment charges related to in-process research and development (IPRD).

In terms of operational changes, BMS experienced a notable shift in its revenue composition. The Growth Portfolio, which includes key products like Opdivo and Eliquis, saw a 12% increase in total revenues, reaching $6.227 billion. However, the Legacy Portfolio faced challenges, with total revenues declining by 6% to $5.277 billion, largely due to generic competition impacting products such as Revlimid and Pomalyst. The company also reported a significant reduction in gross-to-net (GTN) adjustments, which fell to $5.758 billion from $8.988 billion, reflecting improved pricing strategies and reduced rebates.

Strategically, BMS has been focusing on enhancing its product pipeline and operational efficiency. The company announced several positive developments in its clinical trials, including FDA approvals for Sotyktu and Opdivo, as well as promising interim results for multiple therapies in various stages of development. Additionally, BMS is implementing a restructuring plan aimed at streamlining operations and achieving approximately $2 billion in annual cost savings by the end of 2027. This initiative is part of a broader strategy to align resources with high-priority projects and improve overall operational effectiveness.

Geographically, BMS reported a 1% decrease in U.S. revenues, totaling $7.788 billion, while international revenues increased by 11% to $3.444 billion, driven by strong demand for its Growth Portfolio products. The company continues to expand its market presence, with no single country outside the U.S. contributing more than 10% of total revenues. The overall employee headcount remained stable, reflecting the company's commitment to maintaining its workforce while pursuing strategic initiatives.

Looking ahead, BMS anticipates continued revenue growth driven by its innovative product pipeline and strategic investments. However, the company remains cautious about potential regulatory pressures and market conditions that could impact pricing and reimbursement rates. The ongoing implementation of the Inflation Reduction Act and other governmental actions may pose challenges, but BMS is focused on adapting its strategies to navigate these changes effectively. The company is committed to delivering value to shareholders while advancing its mission to provide transformative medicines for patients with serious diseases.